Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review.

Autor:	Inan F; Department of Clinical Pharmacy, Onze Lieve Vrouwe Gasthuis (OLVG) Hospital, Amsterdam., Brunt TM; Amsterdam Medical Center, Amsterdam Institute for Addiction Research, Amsterdam.; Department of Developmental Psychopathology, Behavioral Science Institute, Radboud University, Nijmegen; and., Contrucci RR; Division of Anaesthesiology, Intensive Care and Emergency Medicine, University Medical Center Utrecht, National Poisons Information Center (NVIC), Utrecht, the Netherlands., Hondebrink L; Division of Anaesthesiology, Intensive Care and Emergency Medicine, University Medical Center Utrecht, National Poisons Information Center (NVIC), Utrecht, the Netherlands., Franssen EJF; Department of Clinical Pharmacy, Onze Lieve Vrouwe Gasthuis (OLVG) Hospital, Amsterdam.
Jazyk:	angličtina
Zdroj:	Therapeutic drug monitoring [Ther Drug Monit] 2020 Apr; Vol. 42 (2), pp. 271-281.
DOI:	10.1097/FTD.0000000000000725
Abstrakt:	Background: The novel phenethylamines 4-fluoroamphetamine (4-FA) and 2,5-dimethoxy-4-bromophenethylamine (2C-B) fall in the top 10 most used new psychoactive substances (NPSs) among high-risk substance users. Various phenethylamines and NPS are also highly used in populations with mental disorders, depression, or attention deficit hyperactivity disorder (ADHD). Moreover, NPS use is highly prevalent among men and women with risky sexual behavior. Considering these specific populations and their frequent concurrent use of drugs, such as antidepressants, ADHD medication, and antiretrovirals, reports on potential interactions between these drugs, and phenethylamines 4-FA and 2C-B, were reviewed. Methods: The authors performed a systematic literature review on 4-FA and 2C-B interactions with antidepressants (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, duloxetine, bupropion, venlafaxine, phenelzine, moclobemide, and tranylcypromine), ADHD medications (atomoxetine, dexamphetamine, methylphenidate, and modafinil), and antiretrovirals. Results: Limited literature exists on the pharmacokinetics and drug-drug interactions of 2C-B and 4-FA. Only one case report indicated a possible interaction between 4-FA and ADHD medication. Although pharmacokinetic interactions between 4-FA and prescription drugs remain speculative, their pharmacodynamic points toward interactions between 4-FA and ADHD medication and antidepressants. The pharmacokinetic and pharmacodynamic profile of 2C-B also points toward such interactions, between 2C-B and prescription drugs such as antidepressants and ADHD medication. Conclusions: A drug-drug (phenethylamine-prescription drug) interaction potential is anticipated, mainly involving monoamine oxidases for 2C-B and 4-FA, with monoamine transporters being more specific to 4-FA.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu